MarketWatch.com - Top Stories

Sarepta Therapeutics’ stock falls after patient dies of liver failure

The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.

Mar 18, 2025 - 14:58
 0
Sarepta Therapeutics’ stock falls after patient dies of liver failure
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
Read More

Tags:

Previous Article

Households plans for long-term care, but those plans may not reflect reality

Next Article

Prediction: These 2 Stocks Will Outperform the Market Through 2030

Related Posts

Some market signals aren’t working like they used to. Here’s the one to watch.

Some market signals aren’t working like they used to. H...

Mar 6, 2025  0

Netflix paid $55 million for a show. Prosecutors say the creator blew it on Rolls Royces and crypto.

Netflix paid $55 million for a show. Prosecutors say th...

Mar 18, 2025  0

Are we now in a stock-market correction, pullback or bear market? Here are six charts to watch.

Are we now in a stock-market correction, pullback or be...

Mar 13, 2025  0